ორშაბათი, ივნისი 15, 2026
- Advertisement -
Google search engine
Global Ingredient Risk Index Specialty

Sulforaphane Glucosinolate

Brassica oleracea

Also known as: SGS, Glucoraphanin, Sulforaphane precursor, Broccoli seed extract

LOW RISK 1.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 1.5/10).

02

Safety Profile

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
03

Interactions

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
04

Evidence and Scientific Findings

Overview

Ingredient Overview

Sulforaphane glucosinolate (SGS) is a stable precursor to sulforaphane found in broccoli seed extract. It activates Nrf2 antioxidant pathways. It is generally well tolerated. High doses may affect thyroid iodine uptake in iodine-deficient individuals. It may interfere with the absorption of some thyroid medications. GI discomfort is possible at high doses. Very safe at standard supplement doses.

Classification

Biological and Chemical Classification

Scientific Name
Brassica oleracea
Mechanism

Mechanism of Action

Information not yet available for this ingredient profile.

Clinical Evidence

Clinical Evidence of Effectiveness

Information not yet available for this ingredient profile.

Pharmacokinetics

Pharmacokinetics

Information not yet available for this ingredient profile.

Dosage

Recommended Dosage

Information not yet available for this ingredient profile.

═══════════════════════════════════════════════════════════════════════ -->
05

SETI — Scientific Evidence Transparency Index

SETI Score 46/100
Risk Level High risk
Scientific Confidence Low
Evidence Strength Limited
Key Benefit Specialty
Evidence Reviewed 10 PubMed studies
Scientific Confidence Low
Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 46/100
Risk Level High risk
Evidence Strength Limited
Main Benefit Specialty
Ingredient Sulforaphane Glucosinolate
Scientific name Brassica oleracea
Scientific Evidence Overview
  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or RCT)
  • Main clinical benefit observed: Specialty
  • Evidence consistency: High consistency across studies (100%)
Safety Signals
  • No significant safety signals identified in the reviewed literature.
Evidence Strength Limited
Final Scientific Assessment

The available scientific evidence for Sulforaphane Glucosinolate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Sulforaphane Glucosinolate
Evidence reviewed 10 peer-reviewed studies (last 10 years)
Scientific name Brassica oleracea
46 /100

Total SETI Score

High risk
Evidence quality 10/40
Evidence consistency 20/20
Safety signals 0/20
Study recency 8/10
Evidence transparency 8/10

Evidence Summary

  • 10 studies reviewed
  • 0 high-quality studies (meta-analysis or systematic review)
  • 0 studies identified benefits or no safety concern (GREEN)
  • 10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 26 მარ 2026, 14:10

Evidence Distribution

10 Other / unclassified
  1. Observational / other LOW evidence YELLOW
    Potent antioxidant and anticancer efficacy of Brassica oleracea var acephala extracts: a cytomorphological and antidiabetic assessment. ↗
    Journal Braz J Biol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Shafi S et al.. Potent antioxidant and anticancer efficacy of Brassica oleracea var acephala extracts: a cytomorphological and antidiabetic assessment.. Braz J Biol. 2026. PMID:41880462.
  2. Observational / other LOW evidence YELLOW
    BnaPAP2.C2 plays a novel inhibitory role in anthocyanin accumulation compared to its paralogs in rapeseed (Brassica napus L.). ↗
    Journal Plant J
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Xu L et al.. BnaPAP2.C2 plays a novel inhibitory role in anthocyanin accumulation compared to its paralogs in rapeseed (Brassica napus L.).. Plant J. 2026. PMID:41877443.
  3. Observational / other LOW evidence YELLOW
    A spatiotemporal resolution to genetic redundancy: MIR164 diversification coordinates development and metabolism in Brassica. ↗
    Journal Plant J
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Chen X et al.. A spatiotemporal resolution to genetic redundancy: MIR164 diversification coordinates development and metabolism in Brassica.. Plant J. 2026. PMID:41867071.
  4. Observational / other LOW evidence YELLOW
    Identification of Brassica oleracea germplasm resources resistant to Plutella xylostella (L.). ↗
    Journal Pest Manag Sci
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Li P et al.. Identification of Brassica oleracea germplasm resources resistant to Plutella xylostella (L.).. Pest Manag Sci. 2026. PMID:41859830.
  5. Observational / other LOW evidence YELLOW
    Brassica metabolite priming boosts growth and ion-water homeostasis under salt stress in broccoli. ↗
    Journal J Plant Physiol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Albaladejo-Marico L et al.. Brassica metabolite priming boosts growth and ion-water homeostasis under salt stress in broccoli.. J Plant Physiol. 2026. PMID:41855887.
  6. Observational / other LOW evidence YELLOW
    Functional characterization of BoVML1 uncovers a RER3-related network controlling chloroplast development and leaf morphogenesis in cabbage. ↗
    Journal Plant Physiol Biochem
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Chen G et al.. Functional characterization of BoVML1 uncovers a RER3-related network controlling chloroplast development and leaf morphogenesis in cabbage.. Plant Physiol Biochem. 2026. PMID:41844484.
  7. Observational / other LOW evidence YELLOW
    Broccoli-mediated gold nanoparticles: Eco-friendly synthesis and nano-bio interactions promoting wound healing and targeted cytotoxicity. ↗
    Journal J Genet Eng Biotechnol
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Taay YM et al.. Broccoli-mediated gold nanoparticles: Eco-friendly synthesis and nano-bio interactions promoting wound healing and targeted cytotoxicity.. J Genet Eng Biotechnol. 2026. PMID:41839661.
  8. Observational / other LOW evidence YELLOW
    Herbicidal Activity of the Invasive Weed Malachra capitata L.: Growth Stage Dependence, Bioassay-Guided Fractionation, and Physiological Effects on Seed Germination. ↗
    Journal Plants (Basel)
    Year 2026
    Study type Observational / other
    Evidence strength LOW evidence
    Wichittrakarn P et al.. Herbicidal Activity of the Invasive Weed Malachra capitata L.: Growth Stage Dependence, Bioassay-Guided Fractionation, and Physiological Effects on Seed Germination.. Plants (Basel). 2026. PMID:41829862.
  9. Observational / other LOW evidence YELLOW
    Broccoli. ↗
    Year 2006
    Study type Observational / other
    Evidence strength LOW evidence
    Broccoli.. 2006. PMID:41855365.
  10. Observational / other LOW evidence YELLOW
    Cabbage. ↗
    Year 2006
    Study type Observational / other
    Evidence strength LOW evidence
    Cabbage.. 2006. PMID:30000833.
═══════════════════════════════════════════════════════════════════════ -->
06

Score Transparency

Q × L × D × S × 10 = 1.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

Q
Evidence Quantity 0 / 10
0%

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

L
Evidence Quality 5 / 10
50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

D
Evidence Direction 5 / 10
Benefit
Risk
50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

S
Safety Signals 5 / 10
50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 1.5 / 10

Final GIRI Score for Sulforaphane Glucosinolate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

  • References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
  • Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
  • Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
  • Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
07

Risk Level Classification

LOW RISK 1.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0
MODERATE
3.0–5.5
HIGH
5.5–7.5
CRITICAL
7.5–10
1.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Sulforaphane Glucosinolate

GIRI Score 1.5 / 10

A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Evidence Quantity (Q) 0 / 10 refs

0 approved references.

Evidence Quality (L) 50%

Limited — mostly case reports or animal studies (Level 4–5).

Evidence Direction (D) 50% toward risk

Neutral or mixed — benefit and risk signals roughly balanced.

Safety Signals (S) 0 active signals

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

Regulatory Status No restrictions found

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

LevelScoreMeaning
LOW0.0 – 2.9Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE3.0 – 5.4Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH5.5 – 7.4Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL7.5 – 10Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

შენიექიმი
sheniekimi.ge · PHIG
გამარჯობა 👋
სასურველი სერვისი აირჩიეთ ქვემოთ
⚡ გადაუდებელი შემთხვევა?
მყისიერი სამედიცინო დახმარება
📞 112
🩺
სიმპტომების შეფასება
150 კლინიკური სცენარი · WHO · AHA · NICE · 29 CDR
💉
ვაქცინაციის კალენდარი
WHO · ECDC · NCDC საქართველო 2025
💊
დანამატების შემოწმება
supplement.ge — 2,095 ინგრედიენტი
ℹ️ეს სისტემა ახდენს ტრიაჟს — არა დიაგნოზს. ყოველი გადაწყვეტილება დაფუძნებულია WHO, AHA, NICE, BTS სახელმძღვანელოებზე. ექიმის კონსულტაცია სავალდებულოა.
პირადი ინფორმაცია
სიმპტომების ზუსტი შეფასებისთვის შეიყვანეთ ასაკი და სქესი
👤სავალდებულო
📏 ანთროპომეტრია
სიმაღლე · წონა · BMI — არასავალდებულო
🩺 სასიცოცხლო მაჩვენებლები
წნევა · პულსი · ტემპერატურა · SpO2 — არასავალდებულო
ნორმა: 90–129
ნორმა: 60–100
36–37.2
12–20
≥95%
სიმპტომების შეფასება
აირჩიეთ სცენარი სისტემის მიხედვით
🔍
კითხვა 1 / 1
📋 მტკიცებულებითი საფუძველი
World Health Organization (WHO) — IMAI სახელმძღვანელო
American Heart Association (AHA) / ACC
National Institute for Health and Care Excellence (NICE)
ICD-11 (2025) · World Health Organization
ეს ინსტრუმენტი ახდენს ტრიაჟს — არა დიაგნოზს. სიმპტომები შეიძლება მიუთითებდეს — ეს არ ნიშნავს, რომ დაავადება გაქვთ. ექიმის კონსულტაცია სავალდებულოა.
📰 სიახლეები ყველა ›
ვაქცინაციის კალენდარი
აირჩიეთ ასაკობრივი ჯგუფი
WHO ECDC NCDC 2025
📚წყარო: NCDC საქართველო 17.09.2025 · WHO · ECDC
ასაკობრივი ჯგუფი
📚წყარო: NCDC საქართველო 17.09.2025 · WHO · ECDC
📰 ვაქცინაციის სიახლეები ყველა ›
დანამატების შემოწმება
გადადით supplement.ge-ზე და შეამოწმეთ ნებისმიერი პროდუქტი
SUPPLEMENT.GE
საქართველოს სასურსათო დანამატების უსაფრთხოების შემოწმების სისტემა
📊 2,095 ინგრედიენტი 📦 688 პროდუქტი
supplement.ge-ზე გადასვლა
ახალი ფანჯარა გაიხსნება
რას შეგიძლიათ შეამოწმოთ
🔬
ინგრედიენტის შემოწმება
NIH · EU · FDA · Health Canada მონაცემები
📷
ეტიკეტის სკანირება
AI ამოიცნობს ყველა ინგრედიენტს ფოტოდან
🌍
ქვეყნის მიხედვით სტატუსი
რეგულაცია 14 ქვეყანაში — აშშ, ევროკავშირი, კანადა
⚠️
წამალთან ინტერაქცია
აუცილებელი გაფრთხილებები მიმდინარე მკურნალობისას
✅ supplement.ge — საქართველოში ერთადერთი სრული სისტემა დანამატების უსაფრთხოების შესაფასებლად, PHIG-ის (საზოგადოებრივი ჯანდაცვის ინსტიტუტის) კონტროლით.